NO335317B1 - Anvendelse av natrium meta-arsenitt (NaAsO2) for fremstilling av en farmasøytisk sammensetning for behandling av en fast tumor - Google Patents

Anvendelse av natrium meta-arsenitt (NaAsO2) for fremstilling av en farmasøytisk sammensetning for behandling av en fast tumor Download PDF

Info

Publication number
NO335317B1
NO335317B1 NO20044573A NO20044573A NO335317B1 NO 335317 B1 NO335317 B1 NO 335317B1 NO 20044573 A NO20044573 A NO 20044573A NO 20044573 A NO20044573 A NO 20044573A NO 335317 B1 NO335317 B1 NO 335317B1
Authority
NO
Norway
Prior art keywords
tumor
arsenite
treatment
pharmaceutical composition
preparation
Prior art date
Application number
NO20044573A
Other languages
English (en)
Norwegian (no)
Other versions
NO20044573L (no
Inventor
Sang Bong Lee
Yong Jin Yang
Original Assignee
Sang Bong Lee
Yong Jin Yang
Komipharm Int Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29244880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO335317(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sang Bong Lee, Yong Jin Yang, Komipharm Int Co Ltd filed Critical Sang Bong Lee
Publication of NO20044573L publication Critical patent/NO20044573L/no
Publication of NO335317B1 publication Critical patent/NO335317B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20044573A 2002-04-10 2004-10-22 Anvendelse av natrium meta-arsenitt (NaAsO2) for fremstilling av en farmasøytisk sammensetning for behandling av en fast tumor NO335317B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2002/000231 WO2003086424A1 (en) 2002-04-10 2002-04-10 Pharmaceutical composition comprising arsenite for the treatment of malignancy

Publications (2)

Publication Number Publication Date
NO20044573L NO20044573L (no) 2004-10-22
NO335317B1 true NO335317B1 (no) 2014-11-10

Family

ID=29244880

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044573A NO335317B1 (no) 2002-04-10 2004-10-22 Anvendelse av natrium meta-arsenitt (NaAsO2) for fremstilling av en farmasøytisk sammensetning for behandling av en fast tumor

Country Status (25)

Country Link
US (1) US20050106262A1 (enExample)
EP (2) EP1496918B1 (enExample)
JP (1) JP2005525397A (enExample)
CN (1) CN1298332C (enExample)
AP (1) AP2004003167A0 (enExample)
AU (2) AU2002253713B2 (enExample)
BG (1) BG66356B1 (enExample)
BR (1) BR0215689A (enExample)
CA (1) CA2481602C (enExample)
CY (1) CY1114422T1 (enExample)
DK (2) DK2042182T3 (enExample)
EC (1) ECSP045408A (enExample)
ES (2) ES2944907T3 (enExample)
FI (1) FI1496918T3 (enExample)
HU (1) HU230851B1 (enExample)
IL (2) IL164470A0 (enExample)
LT (1) LT1496918T (enExample)
MX (1) MXPA04009898A (enExample)
NO (1) NO335317B1 (enExample)
NZ (1) NZ536452A (enExample)
PT (2) PT1496918T (enExample)
RO (1) RO123269B1 (enExample)
TN (1) TNSN04198A1 (enExample)
UA (1) UA80426C2 (enExample)
WO (1) WO2003086424A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024488A2 (en) * 2004-08-30 2006-03-09 Interstitial Therapeutics Medical stent provided with inhibitors of atp synthesis
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
US20100249210A1 (en) * 2008-09-30 2010-09-30 Michael Bastiani Methods and compositions related to dlk-1 and the p38 mapk pathway in nerve regeneration
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
PL2475362T3 (pl) * 2009-09-10 2019-09-30 Kominox, Inc. Terapia celowana w nowotworowe komórki macierzyste i raka lekoopornego
RU2012108439A (ru) * 2009-09-18 2013-10-27 Коминокс, Инк. Способы лечения опухолей головного мозга
CN101695501B (zh) * 2009-10-10 2013-08-14 广汉恒宇新材料有限公司 一种纳米尺寸亚砷酸的壳聚糖包载体及其制造方法
CA3094115A1 (en) 2018-03-22 2019-09-26 Komipharm International Australia Pty Ltd Pharmaceutical composition comprising meta arsenite and method of manufacture

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0804928B1 (en) * 1994-02-18 2004-10-20 Tamara Vasilievna Vorobieva Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system
EP1391206B1 (en) * 1997-10-15 2008-07-02 Polarx Biopharmaceuticals, Inc. Pharmaceutical compositions comprising arsenic trioxide for the treatment of non-Hodgkin's lymphoma
CN1119152C (zh) * 1998-08-02 2003-08-27 哈尔滨医科大学第一临床医学院 治疗消化系统肿瘤注射液及其应用

Also Published As

Publication number Publication date
PT1496918T (pt) 2023-05-25
BG66356B1 (bg) 2013-09-30
CY1114422T1 (el) 2016-08-31
DK2042182T3 (da) 2013-08-26
DK1496918T3 (da) 2023-05-15
AU2008255139B2 (en) 2013-10-03
CN1625407A (zh) 2005-06-08
HUP0500199A2 (en) 2007-02-28
PT2042182E (pt) 2013-08-28
ES2944907T3 (es) 2023-06-27
EP1496918A1 (en) 2005-01-19
AP2004003167A0 (en) 2004-12-31
AU2002253713B2 (en) 2008-09-18
ECSP045408A (es) 2006-03-01
BR0215689A (pt) 2005-02-01
EP1496918B1 (en) 2023-02-08
NZ536452A (en) 2007-06-29
JP2005525397A (ja) 2005-08-25
IL164470A (en) 2010-12-30
CN1298332C (zh) 2007-02-07
BG108932A (en) 2005-11-30
TNSN04198A1 (en) 2007-03-12
WO2003086424A1 (en) 2003-10-23
RO123269B1 (ro) 2011-05-30
UA80426C2 (en) 2007-09-25
CA2481602C (en) 2011-06-21
ES2425418T3 (es) 2013-10-15
US20050106262A1 (en) 2005-05-19
AU2002253713A1 (en) 2003-10-27
EP2042182A1 (en) 2009-04-01
CA2481602A1 (en) 2003-10-23
LT1496918T (lt) 2023-05-25
NO20044573L (no) 2004-10-22
MXPA04009898A (es) 2005-06-20
FI1496918T3 (fi) 2023-05-11
IL164470A0 (en) 2005-12-18
AU2008255139A1 (en) 2009-01-08
HUP0500199A3 (en) 2008-03-28
EP2042182B1 (en) 2013-05-22
HU230851B1 (en) 2018-09-28

Similar Documents

Publication Publication Date Title
JP2748333B2 (ja) 抗腫瘍性、抗ウイルス性、抗レトロウイルス性および殺虫性スペルミン誘導体
Wright et al. Synthesis, characterization, and antimicrobial activity of silver carbene complexes derived from 4, 5, 6, 7-tetrachlorobenzimidazole against antibiotic resistant bacteria
Ng et al. Synthesis, characterization, DNA-binding study and anticancer properties of ternary metal (II) complexes of edda and an intercalating ligand
RU2106146C1 (ru) Средство для подавления опухолевого роста
Bykowska et al. Phosphine derivatives of ciprofloxacin and norfloxacin, a new class of potential therapeutic agents
AU2008255139A1 (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
Warżajtis et al. Mononuclear gold (iii) complexes with l-histidine-containing dipeptides: tuning the structural and biological properties by variation of the N-terminal amino acid and counter anion
Karadağ et al. In vitro biological properties and predicted DNA–BSA interaction of three new dicyanidoargentate (i)-based complexes: synthesis and characterization
Kincses et al. Selenocompounds as Potent Efflux Pump Inhibitors on Gram‐positive Bacteria
Bologna et al. Water-soluble platinum phthalocyanines as potential antitumor agents
Kargar et al. Recent advances in the antimicrobial activity of Zn (II) Schiff base complexes
US20080153907A1 (en) Pharmaceutical Composition for the Treatment of Cancer Comprising Lhm-Ra Complex
Aziz et al. Synthesis, crystal structure, antibacterial, cytotoxic, and anticancer activities of new Pd (II) complexes of tri-p-tolyl phosphine with thiones
WO1999018083A1 (en) N,n'-(sulphonyldi-1, 4-phenylen) bis (n'',n''- dimethylformamidin)-1, 2,3,4-tetrahydro- 6-methyl-2, 4-dioxo-5-pyrimidinsulphonate for stimulating cellular metabolism and having an immunotropic and anti-bacterial activity and method for producing the same
RU2277908C1 (ru) Водорастворимое средство, обладающее противовирусной активностью, на основе соединения серебра с цистином и способ его получения
RU2358721C1 (ru) Антинеопластический препарат (варианты)
Keypour et al. Anticancer, antioxidant, and antimicrobial studies and molecular docking of a new hexanuclear Zn (ii) complex, together with its X-ray crystal analysis
AU2008258216A1 (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
RU2441016C1 (ru) Соли 5'-аминокарбонилфосфоната 3'-азидо-3'-дезокситимидина, являющиеся селективными ингибиторами продукции вируса иммунодефицита человека вич-1
CN1523018A (zh) 杂多酸5－氟尿嘧啶盐类抗肿瘤药物及其合成方法
CN120518676A (zh) 一种协同调控多胺摄取和pd-l1糖基化修饰的金属铂杂合体、其制备方法及应用
ZA200408114B (en) Pharmaceutical compositions comprising arsenite for the treatment of malignancy
Bai et al. Novel Oxovanadium Complex VO (hntdtsc)(NPIP): Anticancer Activity and Mechanism of Action on
Benedetti et al. Design, Synthesis, and Anticancer Activity of Fluorescent-Based Dual Function trans-Platinum-NBD Complexes
OA12802A (en) Pharmaceutical composition comprising arsenite forthe treatment of malignancy.

Legal Events

Date Code Title Description
MK1K Patent expired